Adebrelimab after initial treatment for limited-stage small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether continuing a drug called adebrelimab (an immunotherapy) after standard treatment helps keep limited-stage small cell lung cancer from coming back. It compares adebrelimab with the usual approach of just watching and following up.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have limited-stage small cell lung cancer (cancer that has not spread far).
- You must not have had any prior treatment for this cancer.
- You must have at least one tumor that can be measured.
- You must be in good physical condition (able to do daily activities) and have normal organ function.
- You must agree to use effective birth control during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new maintenance drug (adebrelimab) after standard chemo and radiation in patients with limited-stage small cell lung cancer. The goal is to see if it helps keep the cancer from coming back and improves overall survival, compared to standard care.
This trial tests a new drug (adebrelimab) combined with standard chemotherapy and radiation for limited-stage small cell lung cancer. After the initial treatment, the drug is continued to help keep the cancer from coming back.
This trial is for people with limited-stage small cell lung cancer who have finished chemoradiation and still have small amounts of cancer DNA in their blood (called MRD-positive). The study tests a new treatment strategy after chemoradiation, and it may help reduce the chance of the cancer coming back.
This trial tests a new combination of an immunotherapy drug (adebelimab) with chemotherapy as a first treatment for extensive-stage small cell lung cancer. It aims to see if this combination can help control the cancer better than standard care.
This trial tests whether the drug adebrelimab (a type of immunotherapy) can help prevent your lung cancer from coming back after you finish chemotherapy and radiation. It is for people with limited-stage small cell lung cancer (cancer found only in one lung and nearby lymph nodes) that did not grow during initial treatment.
This trial tests a combination of two drugs (adebrelimab and etoposide capsules) as maintenance therapy for people with extensive-stage small cell lung cancer who have not progressed after initial treatment. It may help extend the time before the cancer grows back.
Hear when a new Localized Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.